Skip to main content Help with accessibility Skip to main navigation

All Guidance

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2018
BNF chapter: Central nervous system

Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine - For Attention Deficit Hyperactivity Disorder in adults aged over 17 years and in children and adolescents aged 6 to 17 years

Guanfacine - For Attention Deficit Hyperactivity Disorder in children and adolescents aged 6 to 17 years 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2014
BNF chapter: Central nervous system

Amisulpride, Aripiprazole, Olanzapine, Quetiapine, Oral Risperidone
This shared prescribing guideline for the second-generation antipsychotic medications listed above has been developed with due consideration to the appropriate NICE Clinical Guidelines (CG) e.g. Bipolar Disorder (CG185), Psychosis and Schizophrenia in Children and Young People (CG155), Psychosis and Schizophrenia in Adults (CG178), Schizophrenia- Aripiprazole (TA213), Bipolar Disorder- Adolescents (TA292).

Please note: Morecambe Bay CCG has now adopted this Shared-care guideline for all areas, including South Cumbria. 

 

Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2017
BNF chapter: Central nervous system

Refer to Local Commissioning Policy Before Use

Treatment of Parkinson’s Disease

 

 

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 15 - July - 2020
BNF chapter: Central nervous system
This guideline provides recommendations on the medical management of adults with chronic non-cancer pain.

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2019
BNF chapter: Central nervous system

This guidance does not apply to the use of Sativex® (delta-9-etrahydrocannabinol and cannabidiol) oromucosal spray as an adjunct treatment for moderate to severe spasticity in multiple sclerosis.

**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 19 - July - 2022
BNF chapter: Central nervous system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2018
BNF chapter: Central nervous system

To be read in conjunction with the SPC , NICE TA 217 and NICE CG42

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2016
BNF chapter: Central nervous system

The Lancashire Medicines Management Group does not recommend the prescribing of e-Cigarettes

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - October - 2018
BNF chapter: Central nervous system
**This Guideline is currently under review. For further information please click here**

Formerly the 'North West Headache Management Guideline for Adults'

Not adopted
Adopted
Pending
Not adopted
Adopted
Pending
Adopted
Pending
Date Posted: 14 - September - 2022
BNF chapter: Central nervous system

To be read in conjunction with the LSCMMG guideline ‘Assessing suitability of strong opioid use’

 

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Pending
Pending
The Lancashire and South Cumbria Self-Care and Access to OTC Medicines – Template policy has been developed for use by care homes in Lancashire and South Cumbria. The policy must be reviewed by each care home for suitability and finalised prior to use.
This policy MUST be read in conjunction with the local or care home medicines policy
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - May - 2014
BNF chapter: Central nervous system

Licensed Indications

  1. In the management of acute mania or hypomanic episodes
  2. In the management of episodes of recurrent depressive disorders where treatment with other antidepressants has been unsuccessful
  3. In the prophylaxis against bipolar affective disorders
  4. Control of aggressive behaviours of intentional self-harm.
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2018
BNF chapter: Central nervous system

This is a summary document intended for Primary Care, taken from a more comprehensive document ‘Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) in Primary and Secondary Care. This document should be accessed for additional resources such as the Leaflet for Care Home Staff, assessment forms and flow chart for responding to BPSD.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2018
BNF chapter: Central nervous system

Information contained within this document is largely taken from the PrescQIPP toolkit ‘Reducing Antipsychotics in Dementia and documents available on the Alzheimer’s Society website.

Not adopted
Not adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - July - 2018
BNF chapter: Central nervous system
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Adopted
Date Posted: 14 - June - 2022
BNF chapter: Central nervous system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

Prescribing request from out-of-area specialists to Lancashire GPs where there is an inconsistency with the recommended local and out-of-area colour classification

**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

In developing local commissioning policies, the CCG will commission treatments or services which accord with all of the following principles:

  • Appropriateness
  • Effectiveness
  • Cost-effectiveness
  • Ethics
  • Affordability

A number of treatments which should be considered a LOW PRIORITY are detailed within this policy

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted

Guidance on consensus approaches to managing Palliative Care Symptoms